Commentary|Videos|February 3, 2026

SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations

Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discusses how ESG is evolving from a reporting exercise into an auditable measure of operational readiness, and what that shift means for sponsor expectations, vendor qualification, and supplier governance discipline.

In a video interview with Applied Clinical Trials at the 2026 SCOPE Summit, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discussed how expectations around environmental, social, and governance (ESG) performance are evolving across the clinical trial vendor ecosystem. Johnson explained why ESG is no longer treated as a supplemental reporting exercise but increasingly viewed by sponsors as a readiness and reliability indicator. He also highlighted growing supplier frustration with inconsistent ESG questionnaires and outlined why integrating ESG assessments into existing vendor qualification and control systems may be the most effective path forward.

Editor's note: This transcript is a lightly edited rendering of the original audio/video content. It may contain errors, informal language, or omissions as spoken in the original recording.

ACT: What conversations or themes are you noticing here at SCOPE about ESG in clinical development?

Johnson: I’m noticing a clear shift in how ESG is being viewed. It’s no longer seen as a side report, as it was in the past. It’s now being treated as a readiness test. In one conversation I had with a supplier, they told me they thought they had ESG covered until a sponsor asked a very specific question: Can you show me evidence that I can audit?

That’s the theme I’m seeing. Sponsors want to ensure they’re working with suppliers that have a credible ESG control system in place and that they’re operating with discipline. That’s how sponsors know they can rely on those suppliers.

I’m also noticing some frustration from suppliers around inconsistent ESG requirements and questionnaires that they’re frequently asked to complete. The most productive conversations, however, are about integration—bringing ESG assessments into existing vendor control systems and qualification processes so there’s no additional burden or bureaucracy.


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Introducing The Human Side of Clinical Trials
This pilot episode of The Human Side of Clinical Trials introduces a framework from Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., exploring why operational failures in clinical trials often trace back to gaps in human readiness rather than process design alone.
© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.